Get the Stockscreener App
6.985
2.10%
-0.155
Relay Therapeutics Inc stock is traded at $6.985, with a volume of 353.68K.
It is down -2.10% in the last 24 hours and up +27.55% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$7.14
Open:
$7
24h Volume:
353.68K
Relative Volume:
0.21
Market Cap:
$1.20B
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-2.4946
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
-5.28%
1M Performance:
+27.55%
6M Performance:
+115.08%
1Y Performance:
+19.69%
1-Day Range:
$6.936
$7.25
1-Week Range:
$6.98
$7.64
52-Week Range:
$1.775
$7.64
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
6.98 | 1.23B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.88 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
How Relay Therapeutics Inc. stock compares to growth peersTrade Volume Report & Real-Time Buy Signal Alerts - newser.com
What machine learning models say about Relay Therapeutics Inc.Quarterly Investment Review & Weekly Breakout Stock Alerts - newser.com
How to forecast Relay Therapeutics Inc. trends using time seriesPortfolio Risk Summary & Low Drawdown Trading Techniques - newser.com
How to use a screener to detect Relay Therapeutics Inc. breakouts2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com
Published on: 2025-11-02 22:47:47 - newser.com
Does Relay Therapeutics Inc. show high probability of rebound2025 Momentum Check & Real-Time Chart Pattern Alerts - newser.com
Why retail investors favor Relay Therapeutics Inc. stockJuly 2025 Sentiment & Entry Point Confirmation Alerts - newser.com
Regression analysis insights on Relay Therapeutics Inc. performanceShare Buyback & Consistent Return Strategy Ideas - newser.com
Has Relay Therapeutics Inc. found a price floorJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
Why hedge funds are buying Relay Therapeutics Inc. stockJuly 2025 Selloffs & Verified Trade Idea Suggestions - newser.com
Using Ichimoku Cloud for Relay Therapeutics Inc. technicalsPortfolio Return Summary & Precise Entry and Exit Recommendations - newser.com
Relay Therapeutics Inc.’s volatility index tracking explained2025 Breakouts & Breakdowns & Consistent Income Trade Ideas - newser.com
Backtesting results for Relay Therapeutics Inc. trading strategiesGap Down & Weekly Market Pulse Alerts - newser.com
Key metrics from Relay Therapeutics Inc.’s quarterly dataGap Up & Verified Entry Point Signals - newser.com
Analyzing recovery setups for Relay Therapeutics Inc. investorsJuly 2025 Fed Impact & High Yield Equity Trading Tips - newser.com
Building trade automation scripts for Relay Therapeutics Inc.Bond Market & Technical Pattern Alert System - newser.com
Is Relay Therapeutics Inc. stock a top momentum play2025 Price Momentum & Short-Term Trading Alerts - newser.com
Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 30,897 Shares - MarketBeat
Peter Rahmer Sells 21,394 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Insider Peter Rahmer Sells 19,135 Shares - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 21,664 Shares of Stock - MarketBeat
What drives Relay Therapeutics Inc stock priceValue Traps to Avoid & Join 100,000+ Investors Already Learning - earlytimes.in
Relay Therapeutics Reaches New 52-Week High of $7.64 - Markets Mojo
Relay Therapeutics president sells $225k in stock By Investing.com - Investing.com Canada
Relay Therapeutics president sells $225k in stock - Investing.com
Relay Therapeutics Executives and Director Sell Shares for Tax Obligations - TradingView
Relay Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 - The Manila Times
RLAY insider sells shares; RSU vesting drives tax withholding - Stock Titan
Relay Therapeutics CFO sale: 21,664 shares at $7.29 - Stock Titan
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet - sharewise.com
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rahmer Peter | See remarks |
Oct 28 '25 |
Sale |
7.29 |
19,135 |
139,494 |
358,863 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 28 '25 |
Sale |
7.29 |
21,664 |
157,931 |
313,631 |
| Bergstrom Donald A | President, R&D |
Oct 28 '25 |
Sale |
7.29 |
30,897 |
225,239 |
521,823 |
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):